“Rising Preference for Autologous Bone Marrow Transplantation”
- Autologous bone marrow transplantation is gaining traction due to its lower risk of complications, such as graft-versus-host disease (GVHD), compared to allogeneic transplantation
- These transplants use the patient’s own stem cells, harvested before high-dose chemotherapy or radiation, making them ideal for treating conditions such as lymphoma and multiple myeloma
- In regions with advanced healthcare infrastructure, such as North America and Europe, autologous transplants account for a significant share of procedures, with approximately 60% of bone marrow transplants in the U.S. being autologous between 2015 and 2019
- Improved stem cell harvesting and cryopreservation techniques have enhanced the success rates of autologous transplants, driving their adoption in hospitals and multi-specialty clinics
- For instance, the FDA approval of APHEXDA™ (motixafortide) in September 2023 for mobilizing hematopoietic stem cells in multiple myeloma patients has further boosted autologous transplant efficiency
- Leading transplant centers, such as those in Germany and the U.S., are increasingly offering autologous transplant packages as a cost-effective and safer option for eligible patients
